Upon first listen, nothing much new. He did discuss quite a bit and in more detail about PrEP and cure potential...which both are very encouraging.

Based on his comments in this interview and his previous PI Dr. Sacha interview, I believe that Dr. Sacha will publish his animal study results with Leronlimab that show great results and likely success in PrEP and possibly even an HIV cure eventually. This will or should hopefully bring some needed media attention to the drug and hopefully the stock.

The way NP explained, if used as PrEP, HIV would go away like the flu. I don't know if this means HIV is not present in the hidden reservoirs and die off fairly quickly? For those infected (this has been discussed on this board previously) and potential cure, if Leronlimab keeps viral load suppressed and once the HIV in the hidden reservoirs dies off (seemed like it was several years), then this could potentially lead to a cure? However, in the same breath, if the HIV high-risk behavior still exists, then Leronlimab would need continued as PrEP.

Some discussion on BLA and still states end of August or September. Sounds like they have had some discussions with FDA, but nothing mentioned about 525 mg vs 700 mg decision.